Report Sections

See All Reports

  • HP:0001297: Stroke
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001297: Stroke

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (20)


    Name (Synonyms) Correlation
    drug669 COVID-19 swap test PCR Wiki 0.28
    drug2846 Rehabilitation exercise protocol Wiki 0.28
    drug45 3D Wiki 0.28
    Name (Synonyms) Correlation
    drug2914 Rivaroxaban 2.5 Mg Oral Tablet Wiki 0.28
    drug2915 Rivaroxaban placebo tablets Wiki 0.28
    drug1587 ID NOW vs. Accula Wiki 0.28
    drug2048 MindRhythm Harmony Wiki 0.28
    drug3163 Sofosbuvir Wiki 0.28
    drug1420 Group Lifestyle Balance Wiki 0.28
    drug2919 Robotic therapy Wiki 0.28
    drug3102 Serology Test Wiki 0.28
    drug3951 mHealth Assessments Wiki 0.28
    drug27 1D Wiki 0.28
    drug1986 Mechanical Trombectomy Wiki 0.28
    drug2284 Observation Wiki 0.20
    drug783 Chloroquine or hydroxychloroquine Wiki 0.20
    drug981 Daclatasvir Wiki 0.20
    drug464 Best Practice Wiki 0.12
    drug3603 Usual Care Wiki 0.09
    drug3485 Tocilizumab Wiki 0.05

    Correlated MeSH Terms (28)


    Name (Synonyms) Correlation
    D020521 Stroke NIH 0.90
    D013226 Status Epilepticus NIH 0.28
    D002543 Cerebral Hemorrhage NIH 0.28
    Name (Synonyms) Correlation
    D013345 Subarachnoid Hemorrhage NIH 0.28
    D016757 Death, Sudden, Cardiac NIH 0.28
    D017180 Tachycardia, Ventricular NIH 0.28
    D004827 Epilepsy NIH 0.28
    D003072 Cognition Disorders NIH 0.20
    D013610 Tachycardia NIH 0.20
    D012640 Seizures NIH 0.16
    D009422 Nervous System Diseases NIH 0.16
    D003643 Death, NIH 0.14
    D006470 Hemorrhage NIH 0.14
    D007511 Ischemia NIH 0.11
    D007676 Kidney Failure, Chronic NIH 0.10
    D003324 Coronary Artery Disease NIH 0.10
    D000070642 Brain Injuries, Traumatic NIH 0.10
    D007238 Infarction NIH 0.09
    D001930 Brain Injuries, NIH 0.08
    D029424 Pulmonary Disease, Chronic Obstructive NIH 0.08
    D060825 Cognitive Dysfunction NIH 0.08
    D008173 Lung Diseases, Obstructive NIH 0.08
    D009203 Myocardial Ischemia NIH 0.07
    D014947 Wounds and Injuries NIH 0.05
    D009369 Neoplasms, NIH 0.05
    D007239 Infection NIH 0.01
    D045169 Severe Acute Respiratory Syndrome NIH 0.01
    D018352 Coronavirus Infections NIH 0.01

    Correlated HPO Terms (13)


    Name (Synonyms) Correlation
    HP:0002133 Status epilepticus HPO 0.28
    HP:0002138 Subarachnoid hemorrhage HPO 0.28
    HP:0001342 Cerebral hemorrhage HPO 0.28
    Name (Synonyms) Correlation
    HP:0004756 Ventricular tachycardia HPO 0.28
    HP:0001645 Sudden cardiac death HPO 0.28
    HP:0001649 Tachycardia HPO 0.20
    HP:0001250 Seizure HPO 0.16
    HP:0001677 Coronary artery atherosclerosis HPO 0.11
    HP:0006510 Chronic pulmonary obstruction HPO 0.09
    HP:0006536 Pulmonary obstruction HPO 0.09
    HP:0001268 Mental deterioration HPO 0.08
    HP:0001658 Myocardial infarction HPO 0.07
    HP:0002664 Neoplasm HPO 0.05

    Clinical Trials

    Navigate: Correlations   HPO

    There are 13 clinical trials


    1 Efficacy of an Evidence-based Healthy Lifestyle Intervention for People Following CVA

    The purpose of this RCT is to examine the efficacy of the Group Lifestyle Balance (GLB) program adapted for people with stroke (CVA) on primary (weight) and secondary outcomes at 3, 6, 12 months from enrollment into the program.

    NCT03873467
    Conditions
    1. Stroke
    Interventions
    1. Behavioral: Group Lifestyle Balance
    2. Other: Usual Care
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Description: Will be obtained using the same scale over the study period that is accessible to people with and without a mobility device (e.g., walker; wheelchair).

    Measure: Change in weight

    Time: Baseline, 3, 6, 12 months

    Secondary Outcomes

    Description: Accelerometers will be worn by participants for two weeks around each study visit to objectively track physical activity participation (amount and intensity). Participants will be given the Actigraph accelerometer at the beginning of the study and will be provided with verbal and written instructions.

    Measure: Physical Activity

    Time: Baseline, 3, 6, 12 months

    Description: Arm circumference measured at mid-upper arm following ACSM guidelines. A total of three measurements will be taken and an average of the three will be used. Measurements will be taken in centimeters.

    Measure: Arm Circumference

    Time: Baseline, 3, 6, 12 months

    Description: Using an automatic cuff (average of three readings, patient seated) diastolic and systolic scores will be recorded

    Measure: Blood Pressure

    Time: Baseline, 3, 6, 12 months

    Description: Fasting venous sample will be obtained. Coordinators are trained phlebotomists.

    Measure: Cholesterol

    Time: Baseline, 3, 6, 12 months

    Description: The Framingham Heart Study diabetes risk score will be calculated using predictors including age, gender, fasting glucose, BMI, HDL cholesterol and triglyceride levels, blood pressure, and parental history. Risk score calculator and regression model are free and used in GLB weight-loss trials. Risk score calculator and regression model are free and used in GLB weight-loss studies. Each risk predictor is assigned points ranging from 2-10. Risk factors are combined and a total score is calculated, with higher scores designating greater 8-year risk.The age range for this score is 45 years to 64 years, and therefore only individuals within this age will have calculated scores. Furthermore, the minimum cut-off score is 3.

    Measure: Risk of Diabetes

    Time: Baseline, 3, 6, 12 months

    Description: Assesses walking speed in (m/s) which is correlated to mobility in the community, capacity to perform ADLs, risk of falls, re-hospitalization, and risk of cognitive decline.

    Measure: 10 Meter Walk Test (10MWT)

    Time: Baseline, 3, 6, 12 months

    Description: Assesses distance walked over 6 minutes as a sub-maximal test of aerobic capacity. Endurance is essential to participate in community-based activities.

    Measure: 6 Minute Walk Test (6MWT)

    Time: Baseline, 3, 6, 12 months

    Description: The Multidimensional Scale of Perceived Social Support (MSPSS) is comprised of 12 questions with a 4-item subscale. The MSPSS is designed to assess perception of social support from friends, family, and significant others

    Measure: Perceived Social Support

    Time: Baseline and 12 months

    Description: Measure includes 28 items that assess health practices among people with disabilities and yields a total Health Practices score plus 4 subscales scores regarding Exercise, Nutrition, Health Practices, and Psychological Well Being. Items are rated on a 5-point scale from 0 'not at all' to 4 'completely.' Scores range from 0-28 with higher scores indicating higher exercise self-efficacy.

    Measure: Self-reported activities of health using the Self-Rated Abilities for Health Practice scale

    Time: Baseline and 12 months

    Description: Walk Score® is publicly available and measures the walkability of any address using a patented system. For each address, Walk Score ® analyzes hundreds of walking routes to nearby amenities and awards points based on distance to each amenity. Walk Score® also measures pedestrian friendliness by analyzing population density and road metrics such a block length and intersection density. Scores are given on a scale of 0 to 100.

    Measure: Neighborhood walkability using Walk Score®

    Time: Baseline

    Description: MedGem® is an FDA cleared and validated indirect calorimetry device. It is handheld and measures oxygen consumption (V02) to determine resting metabolic rate (RMR).

    Measure: Resting Metabolic Rate

    Time: Baseline

    Description: The BRFSS is a state-based system of health surveys that collects information on health risk behaviors, preventative health practices, and health care access primarily related to chronic disease and injury. The GLB-TBI uses the two subscales of Healthy Eating and Physical Activity from the 2017 version of the BRFSS. It consists of 14 items.

    Measure: Behavioral Risk Factor Surveillance

    Time: Baseline, 3, 6, 12 months

    Description: Quality of life will be assess using the stroke impact scale (SIS), which assesses 8 dimensions of health-related QOL specific to people post CVA including subscales (using a 5pt Likert scale) assessing strength, memory and thinking, emotion, communication, activities of daily living, mobility, hand function, and participation/role function

    Measure: Participant quality of ife

    Time: Baseline, 6, 12 months

    Description: This inventory consists of 40 life events and asks the participant to recall if any of the events happened within the previous year (e.g., death of spouse; personal illness; change in sleep). Endorsement of these events are totaled and higher scores indicate a greater amount of stressful life events. Point values for the Holmes and Rahe Stress Inventory were weighted and summed for each individual based on scoring instructions. Individuals who scored 150 points or less were categorized as low susceptibility to a health breakdown in the next two years, 151-300 points were 50% chance of health breakdown, and 301 points or more were 80% chance of health breakdown.

    Measure: Stressful Life Events using the Holmes and Rahe Stress Inventory

    Time: Baseline and 12 months

    Description: The MOCA is a brief, 8-section assessment of various cognitive domains including executive function, memory, language, attention, concentration, orientation, and working memory in neurologic populations.Each item on the MOCA is allocated a set of points adding up to 30.

    Measure: Executive Function and Cognition using the Montreal Cognitive Assessment

    Time: Baseline, 3, and 12 months

    Description: The self-reported habit index (SRHI) measures the self-reported perceptions of habit strength for an identified behavior. It consists of 12 items for each selected behavior and uses a 7-point Likert scale from "completely disagree" to "completely agree." Higher totals represent greater perception of habit strength. The SRHI showed high reliability across four studies with alphas of .89, .92, .89, .94, .95, .94, and .85.

    Measure: Habit Formation

    Time: Baseline, 3, and 12 months

    Description: The Modified Rankin Scale (MRS) measures the degree of disability or dependence for daily activities of people who have had a stroke. The MRS is an ordinal scale with six categories ranging from zero (no symptoms) to five (complete physical dependence). A score of six signifies death.

    Measure: Stroke Severity

    Time: Baseline

    Description: The Pain Interference-Short Form is taken from the Patient-Reported Outcomes Measurement Information System (PROMIS). This measure is used to assess adult self-reported consequences of pain and pain consequences (e.g. interference in social, cognitive, emotional, physical and recreational activities). This measure consists of four questions with five response option ranging from one to five. The sum of all responses creates a total raw score. This measure is normed to the US general population.

    Measure: Pain Interference

    Time: Baseline, 3, 6, and 12 months

    Description: The Sleep Disturbance-Short Form 4a is taken from the Patient-Reported Outcomes Measurement Information System (PROMIS) and used to assess adult sleep disturbance profiles. This measure has four questions, each with five response options ranging in value from one to five. The sum of each response creates a total raw score. The measure is normed to the US general population.

    Measure: Sleep Disturbance

    Time: Baseline, 3, 6, 12 months

    Description: Waist circumference will be measured at the umbilicus following ACSM guidelines. A total of three measurements will be taken and an average of the three will be the final measurement used. Measurements will be scored in centimeters.

    Measure: Waist Circumference

    Time: Baseline, 3, 6, and 12 months

    Description: Fasting venous sample will be obtained for hemoglobin a1c to assess average blood sugar level over the past 2-3 months. Coordinators are trained phlebotomists.

    Measure: HbA1c

    Time: Baseline, 3, 6, and 12 months

    Description: Fasting venous sample will be obtained. Coordinators are trained phlebotomists.

    Measure: Triglycerides

    Time: Baseline, 3, 6, 12 months

    Description: Fasting venous sample will be obtained. Coordinators are trained phlebotomists.

    Measure: Blood Glucose

    Time: Baseline, 3, 6, 12 months

    Description: Isrin, Angiogenic factors (VEGF), Total Homocysteine, Lipoprotein-associated phospholipase A2 (Lp-PLA2), ICF-1, Brain derived neurotrophic factor (BDNF), and Tau proteins (total and phosphorylated) will be drawn to assess relationships with outcome variables.

    Measure: Biomarker Analysis

    Time: Baseline, 3, and 6 months

    Description: A modified version of Prochaska and DiClemente's Stages of Change model will be administered to measure readiness for behavior change. The measure consists of two behaviors (eating and exercise) with five questions each related to a stage of change (precontemplation, contemplation, preparation, action, maintenance).

    Measure: Stages of Change

    Time: Baseline, 3, 6, and 12 months

    Description: The metabolic score calculator will be used at all time points to determine the risk for metabolic syndrome. The following variables will be used to determine metabolic risk using the free metabolic risk calculator: gender, race and ethnicity, systolic blood pressure, fasting glucose, triglycerides, high-density lipoprotein (HDL), weight, height, and waist circumference. Scores are calculated are standardized to the general population.

    Measure: Metabolic Score Calculator (MetS)

    Time: Baseline, 3, 6, and 12 months

    Description: This self-report survey was developed by the National Institute of Mental Health. The full survey consists of 64 questions with an open-ended section at the end to elicit concerns and feedback related to the effects of COVID-19. For this current study, however, only sections on Exposure Status (10 items), Life Changes (15 items), and Emotions/Worries (7 items), and the open-ended question will be asked. Questions are asked "over the past two weeks."

    Measure: CRISIS (CoRonavIruS Health Impact Survey) V0.3 Adult Baseline Form

    Time: Up to 12 months

    Description: The Social Isolation Short-Form 4a is taken from the Patient-Reported Outcomes Measurement Information System (PROMIS). This form assesses the perceptions of being "avoided, excluded, detached, disconnected from, or unknown by, others. There is no timeframe for the form. The measure is normed to the US population.

    Measure: PROMIS Social Isolation Short Form 4a

    Time: Up to 12 months

    Description: To assess media exposure and fear of media exposure during COVID-19 we have added 6 questions. These are asked "over the past two weeks." These questions address time spent watching the television, listening to radio, reading the newspaper, and searching the internet and social media. In addition, a 6th question related to fear is asked using a 5-point Likert scale.

    Measure: Media Questionnaire

    Time: Up to 12 months
    2 Novel Training Environment to Normalize Altered Finger Force Direction Post Stroke

    Despite the functional importance, fingertip forces are rarely explicitly addressed with feedback in therapy. This gap in treatment is due to a lack of tools to provide explicit feedback on patients' volitional finger force generation. To address this unmet need, the investigators developed a novel tool for practice of volitional three-dimensional (3D) force generation with explicit feedback. The objective of this project is to determine if 3D finger force training is an effective tool in restoring hand function post stroke.

    NCT03995069
    Conditions
    1. Stroke
    Interventions
    1. Behavioral: 3D
    2. Behavioral: 1D
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Description: a clinical assessment for upper extremity function

    Measure: Action Research Arm Test (ARAT)

    Time: 3rd baseline to within 1 week post intervention

    Other Outcomes

    Description: a clinical assessment for upper extremity function.

    Measure: Box and Block Test

    Time: 3rd baseline to within 1 week post intervention

    Description: Angular deviation of the grip force vector from the target direction

    Measure: Force Direction

    Time: 3rd baseline to within 1 week post intervention

    Description: a clinical assessment for upper extremity function

    Measure: Action Research Arm Test

    Time: 3rd baseline to 1 month post intervention

    Description: a clinical assessment for upper extremity function.

    Measure: Box and Block Test

    Time: 3rd baseline to 1 month post intervention
    3 Rivaroxaban Plus ASA Efficacy and Safety in Embolic Stroke of Undetermined Source :A Randomized, Double Blind, Placebo Controlled, Pilot Study

    Approximately 17% of all patients with stroke are classified as having ESUS, which is associated with a considerable rate of stroke recurrence 4-5 % per year. Despite recent scientific advances in acute ischemic stroke treatment in recent decades,consensus treatment of all guidelines is still ASA

    NCT04273516
    Conditions
    1. Stroke
    2. Prevention
    Interventions
    1. Drug: Rivaroxaban 2.5 Mg Oral Tablet
    2. Drug: Rivaroxaban placebo tablets
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Description: Number of stroke events during 1 year of study

    Measure: Rate of stroke recurrence

    Time: Rate of stroke recurrence during one year fallow up

    Description: Rate of major bleeding according to criteria of the International Society of Thrombosis and Hemostasis

    Measure: Rate of major bleeding

    Time: During 1 year of study

    Secondary Outcomes

    Description: Number of stroke or systemic embolisms recurrence during 1 year of study

    Measure: Rate of stroke or systemic embolisms

    Time: During 1 year of study

    Description: Number of all cause mortality during study

    Measure: Mortality rate

    Time: During 1year of study

    Description: Rate of non-major bleeding according to criteria of the International Society of Thrombosis and Hemostasis

    Measure: Rate of non-major bleeding

    Time: During 1year of study

    Description: Rate of ICH during study

    Measure: Rate of intracranial bleeding

    Time: During 1year of study

    Description: Rate of fatal bleeding in any site

    Measure: Rate of fatal bleeding

    Time: During 1 year of study
    4 Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial

    This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

    NCT04361552
    Conditions
    1. Cerebrovascular Accident
    2. Chronic Obstructive Pulmonary Disease
    3. Chronic Renal Failure
    4. Coronary Artery Disease
    5. Diabetes Mellitus
    6. Malignant Neoplasm
    7. SARS Coronavirus 2 Infection
    Interventions
    1. Other: Best Practice
    2. Biological: Tocilizumab
    MeSH:Infection Neoplasms Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Stroke Kidney Failure, Chronic Coronary Artery Disease
    HPO:Chronic pulmonary obstruction Coronary artery atherosclerosis Neoplasm Pulmonary obstruction Stroke

    Primary Outcomes

    Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.

    Measure: 7-day length of invasive mechanical ventilation (MV)

    Time: Up to 7 days

    Description: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: 30-day mortality rate

    Time: Up to 30-day after randomization

    Secondary Outcomes

    Description: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of intensive care (ICU) transfer

    Time: Up to 2 years

    Description: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of invasive mechanical ventilation

    Time: Up to 2 years

    Description: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of tracheostomy

    Time: Up to 2 years

    Description: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test

    Measure: Length of ICU stay

    Time: Up to 2 years

    Measure: Length of hospital stay

    Time: Up 2 years
    5 Acute Cardiovascular Events Triggered by COVID-19-Related, Non-infectious Stress The Jordan COVID-9 caRdiovascular Events (JoCORE) Study

    The current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.

    NCT04368637
    Conditions
    1. Acute Myocardial Infarction
    2. Ventricular Tachycardia
    3. Sudden Cardiac Death
    4. Stroke, Acute
    MeSH:Stroke Myocardial Infarction Tachycardia Tachycardia, Ventricular Death, Sudden, Cardiac Infarction Death
    HPO:Myocardial infarction Stroke Sudden cardiac death Tachycardia Ventricular tachycardia

    Primary Outcomes

    Description: Acute myocardial infarction as diagnosed by ST segment elevation or depression or inverted T wave on 12-lead EKG and elevated levels of cardiac troponins above the 99% of the normal values. A. Acute MI (STEMI and NSTEMI). B. Aborted on non-aborted sudden cardiac death not attributed to a known etiology. C. Sustained or non-sustained ventricular tachy-arrhythmia not attributed to a known etiology. D. ICD shocks. 3. Absence of suspected or confirmed infection with the COVID19 virus. 4. Definite physical or psycho-social stressful trigger appearing in relation to the COVID-19 situation (lock down stress, financial stress, anger, depression, fear, sorrow, death of a significant person, eating binges, smoking binges, physical stress [carrying walking for shopping and carrying excess weights] ..etc) as judged by a unanimous agreement of three investigators in the steering committee.

    Measure: Acute cardiovascular event triggered by COVID-19 stress

    Time: 4 months

    Description: Typical ventricular tachycardia on 12-lead EKG or EKG monitor.

    Measure: Ventricular tachycardia

    Time: 4 months

    Description: acute neurological symptoms of hemiparesis or dysrthria due to brain ischemia proven by computerized tomography or magnatic resonance

    Measure: acute stroke

    Time: 4 months

    Description: Finding an episode of ventricular tachycardia on interrogation of ICD tracing

    Measure: Implantable cardioverter defibrillator (ICD) shock

    Time: 4 months
    6 Impact of th Covid-19 Epidemic on Acute Stroke Management

    The Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2. It appears in November 2019 in the city of Wuhan, China, and spreads worldwide from February 2020. The first cases of infection in France were confirmed on 24 January 2020. As of April 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. The most affected regions are Ile de France and the Grand Est (in particular the Haut-Rhin department). Containment of the entire French population was introduced on 17 March, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units. This unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. It appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic. However, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).

    NCT04370197
    Conditions
    1. Stroke, Acute
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Measure: Study of the effect of pandemic covid-19 on the management of stroke patients

    Time: 1 month
    7 Stroke Rehabilitation Outcome During COVID-19 Lockdown

    COVID-19 has a big impact on individuals and society as a whole. Especially persons with (multiple) comorbidities such as stroke are affected. The impact of COVID-19 on stroke rehabilitation delivery and stroke patients' functioning is unclear.

    NCT04373109
    Conditions
    1. Stroke
    2. Rehabilitation
    3. COVID-19
    4. Cohort Studies
    Interventions
    1. Behavioral: Observation
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions

    Measure: Rehabilitation data

    Time: 3 month after start lockdown

    Description: Patient-reported upper limb use in daily life

    Measure: Motor Activity Log - 14 Item Version

    Time: 3 month after start lockdown

    Description: Patient-reported engagement in physical activity in daily life

    Measure: International Physical Activity Questionnaire

    Time: 3 month after start lockdown

    Description: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity

    Measure: Patient-Reported Outcomes Measurement Information System - 29 Version

    Time: 3 month after start lockdown

    Secondary Outcomes

    Description: Patient-reported global rating of physical activity engagement and upper limb use in daily life

    Measure: Global Rating of Perceived Changes (physical activity engagement and upper limb use)

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Self-reported questionnaire regarding severity of fatigue and its influence on the performance of daily life activities

    Measure: Fatigue Severity Scale

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Depression and anxiety

    Measure: Hospital Anxiety and Depression Scale

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Assesses cognitive functions

    Measure: Montreal Cognitive Assessment

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Classification regarding the ability to walk independently, with or without a walking aid and takes the type of walking surface into account

    Measure: Functional Ambulation Categories

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Gait speed and cadence

    Measure: Ten-Meter Walk Test

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Measures the ability of patients to make postural adjustments (e.g, move in bed), transfer (e.g. be-tween bed to chair), walk, and use stairs

    Measure: Rivermead Mobility Index

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Self-reported measure in which patients rate how confident they are in maintaining balance when performing 16 daily life tasks

    Measure: Activities-specific Balance Confidence Scale

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Upper and lower limb motor function

    Measure: Fugl-Meyer Motor Assessment

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Upper limb capacity

    Measure: Action Research Arm Test

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Global disability

    Measure: modified Rankin Scale

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Neurological impairments

    Measure: National Institutes of Health Stroke Scale

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions

    Measure: Rehabilitation data

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

    Description: Patient-reported upper limb use in daily life

    Measure: Motor Activity Log - 14 Item Version

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

    Description: Patient-reported engagement in physical activity in daily life

    Measure: International Physical Activity Questionnaire

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

    Description: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity

    Measure: Patient-Reported Outcomes Measurement Information System - 29 Version

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown
    8 COVID-19 Prevalence, Morbidity and Long Term Cognitive Deficits in Consecutive Patients Presenting With Acute Neurological Symptoms

    The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms

    NCT04377425
    Conditions
    1. Neurological Diseases or Conditions
    2. Stroke, Acute
    3. Seizure Disorder
    Interventions
    1. Diagnostic Test: COVID-19 swap test PCR
    MeSH:Stroke Seizures Nervous System Diseases Epilepsy Cognition Disorders Cognitive Dysfunction
    HPO:Bilateral tonic-clonic seizure Cognitive impairment Focal sensory seizure Focal-onset seizure Generalized-onset seizure Mental deterioration Seizure Stroke

    Primary Outcomes

    Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)

    Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms

    Time: 6 months

    Secondary Outcomes

    Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients

    Measure: Three months cognitive function of COVID-19 positive patients

    Time: 3 months

    Description: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)

    Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients

    Time: 6 months

    Description: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.

    Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients

    Time: 6 months

    Description: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients

    Measure: Anosmia in COVID-19 positive patients

    Time: 6 months

    Description: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls

    Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection

    Time: 24 months

    Description: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis

    Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients

    Time: 24 months
    9 Upper Limb Robotic Rehabilitation in Stroke Survivors Using a Portable Device During the COVID-19 Outbreak. A Feasibility Study

    The COVID-19 outbreak requires a rapid re-shaping of the entire organization of the rehabilitation services. This includes the design and planning of appropriate rehabilitation settings, intervention and logistics for organizing space for patients. The aims of this study are: (a) to evaluate the feasibility of the bedside use of a novel rehabilitation device for upper limb in patients with stroke; (b) to evaluate the motor and cognitive outcomes of the treatment; (c) to validate the instrumental outcomes provided by the device.

    NCT04392453
    Conditions
    1. Stroke
    Interventions
    1. Device: Robotic therapy
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Description: It is a tool for measuring the usability

    Measure: System Usability Scale (SUS)

    Time: After 30 rehabilitation sessions

    Description: It is a tool for measuring the acceptability.

    Measure: Technology Acceptance Model (TAM)

    Time: After 30 rehabilitation sessions

    Description: It is a tool for measuring the satisfaction.

    Measure: Likert Scale

    Time: After 30 rehabilitation sessions

    Secondary Outcomes

    Description: The Fugl-Meyer Assessment is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treatment.

    Measure: Fugl-Meyer Assessment for upper extremity (FMA-UE)

    Time: At baseline; after 30 rehabilitation sessions

    Description: It is a clinical instrument for characterizing the strength of the paretic upper extremity following stroke.

    Measure: Motricity Index for the upper extremity (MI-UE)

    Time: At baseline; after 30 rehabilitation sessions

    Description: It is a clinical instrument for characterizing upper limb spasticity. Shoulder, elbow and wrist spasticity will be assessed.

    Measure: Modified Ashworth Scale (MAS)

    Time: At baseline; after 30 session rehabilitation sessions

    Description: It is a unidimensional measure of pain intensity in adults.

    Measure: Numeric Pain Rating Scale (NPRS)

    Time: At baseline; after 30 rehabilitation sessions

    Description: It is a measure of independence in activities of daily living.

    Measure: Modified Barthel Index (mBI)

    Time: At baseline; after 30 rehabilitation sessions

    Description: It is a widely used screening assessment for detecting cognitive impairment.

    Measure: Montreal Cognitive Assessment (MoCA)

    Time: At baseline; after 30 rehabilitation sessions

    Description: The kinematics of the end-effector of the robot will be acquired during point-to-point tasks.

    Measure: Kinematic parameters

    Time: At baseline (twice, one day apart); after 10 rehabilitation sessions; after 20 rehabilitation sessions; after 30 rehabilitation sessions
    10 Endovascular Thrombectomy in COVID-19 Infected Patients: Intrahospital and Peri-operative Outcomes

    About 5% of COVID-19 patients may present symptoms related to acute ischemic stroke (AIS). Treatment-management and outcomes related to mechanical thrombectomy (MT) for COVID-19 infected patients harboring large vessel occlusion is largely unknown. This multicentric study aims to investigate morbidity, mortality and neurological outcomes after MT performed in patients with COVID-19 infection.

    NCT04406090
    Conditions
    1. Ischemic Stroke
    2. Covid 19
    Interventions
    1. Other: Mechanical Trombectomy
    MeSH:Stroke Ischemia
    HPO:Stroke

    Primary Outcomes

    Description: Intrahospital mortality after MT for COVID-19 infected patients harboring large vessel occlusion

    Measure: Intrahospital mortality

    Time: 1day

    Description: short-term morbidity after MT for COVID-19 infected patients harboring large vessel occlusion

    Measure: short-term morbidity

    Time: 1 day

    Secondary Outcomes

    Description: Angiographic success after MT for COVID-19 infected patients harboring large vessel occlusion

    Measure: Angiographic success

    Time: 1 day
    11 EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic

    Prehospital providers encounter patients with suspected stroke frequently. Stroke and COVID-19 are related potentially putting these healthcare workers at risk of COVID-19 infection. In addition, prehospital providers need tools to help triage large vessel stroke patients to comprehensive stroke centers.

    NCT04445493
    Conditions
    1. Stroke, Acute
    2. COVID-19
    Interventions
    1. Device: MindRhythm Harmony
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Measure: Prevalence of COVID-19 infection in suspected stroke population

    Time: Through Study Completion, an average of 6 months

    Description: Proportion of head pulse studies deemed of high quality for further analysis

    Measure: Quality head pulse recordings

    Time: Through Study Completion, an average 6 months
    12 Physiotherapy as a Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study

    Background: Coronavirus (CoViD-19) positive stroke survivors (SSv) with comorbidities faces possibility for mortality. Study reports success of physiotherapy in CoViD-19 positive SSv with multiple comorbidities. Methods: This clinical controlled study involve a minimum of 30 SSv and 30 age and sex-matched non-stroke individuals with multiple comorbidities with CoViD-19 status confirmed using Real-Time Quantitative-Polymerase Chain Reaction. The Cycle Threshold (CT) and nucleic acid content in the test sample (NA) will be recorded from the virology test results. Their exercise endurance, exercise capacities and quality of life will be assessed using 3-minutes' walk test and 3-meters test and Stroke Specific Quality of Life Questionnaire. Measurements will be taken at every three days intervals from admission to discharge from hospital-isolation. They will receive their normal treatments for CoViD-19 in addition to daily Physiotherapy for the SSv delivered through E-Platform. the Zoom and the WhatsApp video platforms will be used for the interactions between the physiotherapists and the participants. A pre-tested exercise protocol for stroke patients developed by the Stroke and Nervous System Disorders research group of the University of Lagos, Nigeria will be used for the E-exercises. The exercise package will be loaded into the phones of the participants at hospital admission. The Physiotherapists will lead in the exercises through video interaction will the participants watches the video programme. Their risks for respiratory complications (RC), ventilation (RV) and death (RD) will be analysed. Data will be analysed using independent t-test, Analysis of Co-Variance, and multivariate retrogression, survival analyses, Friedman Analysis of Variance and MannWithney U test (95% Confident Interval). Anticipated Outcomes: It is anticipated that the outcome of this study will provide evidence for inclusion of Physiotherapy in the acute management of individuals tested positive for CoViD-19 most important for the stroke survivors tested positive for CoViD-19 at acute stage to reduce the odds of developing complications expedite discharge and reduce odd of death.

    NCT04471831
    Conditions
    1. Corona Virus Infection
    2. Stroke
    Interventions
    1. Other: Rehabilitation exercise protocol
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Stroke
    HPO:Stroke

    Primary Outcomes

    Description: The CT value of a reaction is defined as the cycle number when the fluorescence of a PCR product can be detected above the background signal. The CT value is associated with the amount of PCR product in the reaction. The lower the CT value, the more PCR product that is present. It does not have unit of measurement

    Measure: Cycle Threshold (CT) values as recorded from the series of the qRT-PCR

    Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

    Description: This is the inverse of the Cycle Threshold. It does not have unit of measurement.

    Measure: Nucleic acid values as calculated from the Cycle Threshold recorded from the series of the qRT-PCR

    Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

    Description: Perceived life experience by the participants in relation to the present situation. It does not have unit of measurement.

    Measure: Quality of Life perception

    Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

    Description: The maximum amount of physical exertion that a patient can sustain. It will be tested using the 3-metre walk test. This is the time taken to complete a 3-metre distance. The unit of measurement is in seconds

    Measure: Exercise capacity

    Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

    Description: The maximum length a patient can sustain an exercise procedure, It will be tested using the 3-minutes' walk test This is the distance covered within a 3-minute walk. The unit of measurement is in metres

    Measure: Exercise endurance

    Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented
    13 Severe Neurologic Injury Outcomes During COVID-19 Crisis

    A prospective cohort minimal risk study to determine the impact of the COVID-19 crisis on outcomes of neurologically injured ICU patients.

    NCT04496076
    Conditions
    1. Sars-CoV2
    2. Severe Neurologic Injury
    3. Ischemic Stroke
    4. Hemorrhagic Stroke
    5. Intracerebral Hemorrhage
    6. Subarachnoid Hemorrhage
    7. Traumatic Brain Injury
    8. Status Epilepticus
    MeSH:Stroke Brain Injuries Brain Injuries, Traumatic Subarachnoid Hemorrhage Cerebral Hemorrhage Status Epilepticus Hemorrhage Wounds and Injuries
    HPO:Cerebral hemorrhage Status epilepticus Stroke Subarachnoid hemorrhage

    Primary Outcomes

    Measure: In-hospital Mortality

    Time: At hospital discharge, approximately 1 month

    Measure: 30-day mortality

    Time: 30 days post-hospital discharge

    Secondary Outcomes

    Description: Care treatment such as ventilator use, intubation, and/or tracheostomy

    Measure: Limitations of patient care- Frequency of care not being provided

    Time: During In-hospital course, up to 1 month

    Measure: Limitations of patient care- Conversion of DNR/DNI/CMO status

    Time: During In-hospital course, up to 1 month

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook